Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Aug;106(4):917–923. doi: 10.1111/j.1476-5381.1992.tb14435.x

Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.

D M Vanags 1, S E Rodgers 1, E M Duncan 1, J V Lloyd 1, F Bochner 1
PMCID: PMC1907675  PMID: 1393289

Abstract

1. We have used dose-response curves to quantitate the potentiation of adenosine 5'-diphosphate (ADP)-induced aggregation and thromboxane (TXA2) generation by 5-hydroxytryptamine (5-HT) and adrenaline in human citrated platelet-rich plasma. We have also quantitated the inhibition of these responses by aspirin, ketanserin and yohimbine, singly and in pairs. 2. Ketanserin (5 microM) inhibited TXA2 production and the second wave of platelet aggregation induced by a range of concentrations of ADP alone. This indicates that endogenous 5-HT, released from the platelet dense granules, contributes significantly to responses induced by ADP. 3. When 5-HT (10 microM) was added before ADP, a lower concentration of ADP was required to cause 50% aggregation and TXA2 generation. The ratio of ADP concentrations (CR) to cause 50% aggregation in the presence and absence of 5-HT was 2.1 when only added 5-HT was considered, and 5.0 when endogenous 5-HT was also taken into account. 4. Potentiation of ADP-induced aggregation by 5-HT also occurred in the presence of aspirin, resulting in a CR of 2.3. As expected, ketanserin inhibited potentiation by 5-HT in the presence and absence of aspirin. Although aspirin caused substantial inhibition of aggregation induced by ADP and 5-HT (CR 3.4), further inhibition occurred when ketanserin was also present (CR 6.5). 5. A subthreshold concentration of adrenaline (0.25 microM) caused substantial potentiation of ADP-induced aggregation in the absence (CR 4.0) and presence (CR 2.0) of aspirin. As expected, yohimbine (9 microM) inhibited this potentiation.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
917

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardlie N. G., Cameron H. A., Garrett J. Platelet activation by circulating levels of hormones: a possible link in coronary heart disease. Thromb Res. 1984 Nov 15;36(4):315–322. doi: 10.1016/0049-3848(84)90322-0. [DOI] [PubMed] [Google Scholar]
  2. Arnout J., Van Russelt M., Deckmyn H., Vermylen J., Fiocchi R., Lijnen P., Amery A. Platelet hypersensitivity to serotonin after prolonged ketanserin intake? J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S20–S22. doi: 10.1097/00005344-198500077-00006. [DOI] [PubMed] [Google Scholar]
  3. Asano M., Hidaka H. Potentiation of the contractile response to acetylcholine in aortic strips by low concentrations of vascular contractile agonists. Br J Pharmacol. 1980 Aug;69(4):639–646. doi: 10.1111/j.1476-5381.1980.tb07915.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berlin I., Crespo-Laumonnier B., Cournot A., Landault C., Aubin F., Legrand J. C., Puech A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol Ther. 1991 Apr;49(4):362–369. doi: 10.1038/clpt.1991.42. [DOI] [PubMed] [Google Scholar]
  5. Bevan J., Heptinstall S. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. Thromb Res. 1983 Jun 1;30(5):415–423. doi: 10.1016/0049-3848(83)90175-5. [DOI] [PubMed] [Google Scholar]
  6. Britt S. G., Gonias S. L., Sanders J. M., Vandenberg S. R. Agonist and antagonist activities of arylpiperazines at human platelet serotonin2 receptors. J Pharmacol Exp Ther. 1988 Dec;247(3):965–970. [PubMed] [Google Scholar]
  7. Cameron H. A., Ardlie N. G. The facilitating effects of adrenaline on platelet aggregation. Prostaglandins Leukot Med. 1982 Jul;9(1):117–128. doi: 10.1016/0262-1746(82)90077-4. [DOI] [PubMed] [Google Scholar]
  8. Da Prada M., Picotti G. B. Content and subcellular localization of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma. Br J Pharmacol. 1979 Apr;65(4):653–662. doi: 10.1111/j.1476-5381.1979.tb07878.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Clerck F., Xhonneux B. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro. Agents Actions. 1986 Mar;17(5-6):515–526. doi: 10.1007/BF01965524. [DOI] [PubMed] [Google Scholar]
  10. De Clerck F., Xhonneux B., Leysen J., Janssen P. A. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol. 1984 Sep 1;33(17):2807–2811. doi: 10.1016/0006-2952(84)90699-3. [DOI] [PubMed] [Google Scholar]
  11. De Clerck F., Xhonneux B., Tollenaere J. P., Janssen P. A. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH. Thromb Res. 1985 Dec 1;40(5):581–596. doi: 10.1016/0049-3848(85)90297-x. [DOI] [PubMed] [Google Scholar]
  12. Draskóczy P. R., Trendelenburg U. The uptake of l- and d-norepinephrine by the isolated perfused rabbit heart in relation to the stereospecificity of the sensitizing action of cocaine. J Pharmacol Exp Ther. 1968 Jan;159(1):66–73. [PubMed] [Google Scholar]
  13. Fitzgerald D. J., Roy L., Catella F., FitzGerald G. A. Platelet activation in unstable coronary disease. N Engl J Med. 1986 Oct 16;315(16):983–989. doi: 10.1056/NEJM198610163151602. [DOI] [PubMed] [Google Scholar]
  14. Fleming W. W., Westfall D. P., De la Lande I. S., Jellett L. B. Log-normal distribution of equiefective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther. 1972 May;181(2):339–345. [PubMed] [Google Scholar]
  15. Glusa E., Markwardt F. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents. Biomed Biochim Acta. 1984;43(2):215–220. [PubMed] [Google Scholar]
  16. Golino P., Ashton J. H., Glas-Greenwalt P., McNatt J., Buja L. M., Willerson J. T. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation. 1988 Mar;77(3):678–684. doi: 10.1161/01.cir.77.3.678. [DOI] [PubMed] [Google Scholar]
  17. Grant J. A., Scrutton M. C. Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature. 1979 Feb 22;277(5698):659–661. doi: 10.1038/277659a0. [DOI] [PubMed] [Google Scholar]
  18. Herd C. M., Rodgers S. E., Lloyd J. V., Bochner F., Duncan E. M., Tunbridge L. J. A dose-ranging study of the antiplatelet effect of enteric coated aspirin in man. Aust N Z J Med. 1987 Apr;17(2):195–200. doi: 10.1111/j.1445-5994.1987.tb00040.x. [DOI] [PubMed] [Google Scholar]
  19. Kinlough-Rathbone R. L., Packham M. A., Mustard J. F. Synergism between platelet aggregating agents: the role of the arachidonate pathway. Thromb Res. 1977 Nov;11(5):567–580. doi: 10.1016/0049-3848(77)90016-0. [DOI] [PubMed] [Google Scholar]
  20. Lanza F., Cazenave J. P. Studies of alpha 2-adrenergic receptors of intact and functional washed human platelets by binding of 3H-dihydroergocryptine and 3H-yohimbine--correlation of 3H-yohimbine binding with the potentiation by adrenaline of ADP-induced aggregation. Thromb Haemost. 1985 Aug 30;54(2):402–408. [PubMed] [Google Scholar]
  21. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  22. Mehta J. L. Platelet activation in unstable angina: role of thromboxane A2 and other mediators of vasoconstriction. J Am Coll Cardiol. 1990 Mar 1;15(3):727–729. doi: 10.1016/0735-1097(90)90653-7. [DOI] [PubMed] [Google Scholar]
  23. Meyers K. M., Holmsen H., Seachord C. L. Comparative study of platelet dense granule constituents. Am J Physiol. 1982 Sep;243(3):R454–R461. doi: 10.1152/ajpregu.1982.243.3.R454. [DOI] [PubMed] [Google Scholar]
  24. Michal F., Motamed M. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline. Br J Pharmacol. 1976 Feb;56(2):209–218. doi: 10.1111/j.1476-5381.1976.tb07444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mills D. C., Robb I. A., Roberts G. C. The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J Physiol. 1968 Apr;195(3):715–729. doi: 10.1113/jphysiol.1968.sp008484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mills D. C., Roberts G. C. Effects of adrenaline on human blood platelets. J Physiol. 1967 Nov;193(2):443–453. doi: 10.1113/jphysiol.1967.sp008369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Osmani A. H., Clare K. A., Scrutton M. C. Synergistic interaction and platelet inhibitory agonists. Thromb Res. 1983 Sep 1;31(5):665–674. doi: 10.1016/0049-3848(83)90097-x. [DOI] [PubMed] [Google Scholar]
  28. Owen J. A., Nakatsu S. L., Fenemore J., Condra M., Surridge D. H., Morales A. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol. 1987;32(6):577–582. doi: 10.1007/BF02455991. [DOI] [PubMed] [Google Scholar]
  29. Persson B., Heykants J., Hedner T. Clinical pharmacokinetics of ketanserin. Clin Pharmacokinet. 1991 Apr;20(4):263–279. doi: 10.2165/00003088-199120040-00002. [DOI] [PubMed] [Google Scholar]
  30. Rao G. H., Johnson G. J., White J. G. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prostaglandins Med. 1980 Jul;5(1):45–58. doi: 10.1016/0161-4630(80)90090-7. [DOI] [PubMed] [Google Scholar]
  31. Rao G. H., Reddy R. K., White J. G. Low dose aspirin, platelet function and prostaglandin synthesis: influence of epinephrine and alpha adrenergic blockade. Prostaglandins Med. 1981 May;6(5):485–494. doi: 10.1016/0161-4630(81)90107-5. [DOI] [PubMed] [Google Scholar]
  32. Schächter M., Godfrey P. P., Minchin M. C., McClue S. J., Young M. M. Serotonergic agonists stimulate inositol lipid metabolism in rabbit platelets. Life Sci. 1985 Oct 28;37(17):1641–1647. doi: 10.1016/0024-3205(85)90484-9. [DOI] [PubMed] [Google Scholar]
  33. Steen V. M., Holmsen H. Synergism between thrombin and epinephrine in human platelets: different dose-response relationships for aggregation and dense granule secretion. Thromb Haemost. 1985 Oct 30;54(3):680–683. [PubMed] [Google Scholar]
  34. Thomas D. P. Effect of catecholamines on platelet aggregation caused by thrombin. Nature. 1967 Jul 15;215(5098):298–299. doi: 10.1038/215298a0. [DOI] [PubMed] [Google Scholar]
  35. Thompson N. T., Scrutton M. C., Wallis R. B. Synergistic responses in human platelets. Comparison between aggregation, secretion and cytosolic Ca2+ concentration. Eur J Biochem. 1986 Dec 1;161(2):399–408. doi: 10.1111/j.1432-1033.1986.tb10459.x. [DOI] [PubMed] [Google Scholar]
  36. Watts S. E., Tunbridge L. J., Duncan E. M., Lloyd J. V. Storage of platelets for tests of platelet function: comparison of two methods of pH control. Thromb Res. 1985 Jan 1;37(1):73–83. doi: 10.1016/0049-3848(85)90034-9. [DOI] [PubMed] [Google Scholar]
  37. de Clerck F., David J. L., Janssen P. A. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions. 1982 Jul;12(3):388–397. doi: 10.1007/BF01965409. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES